Radiation Oncologist, Associate Professor at @NorthwesternMed @LurieCancer. #radonc #btsm #pcsm tweets = own opinion

Joined April 2017
180 Photos and videos
Sean Sachdev, MD retweeted
Mar 10
Adaptive radiotherapy involves modifying treatment plans to account for changes in anatomical geometry that are not adequately mitigated with changes in alignment. Online adaptive radiotherapy capitalizes on advances in image guidance, real-time tumor tracking, and the enhanced speed of multiple steps in radiotherapy planning and delivery workflows (seen in image). Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
1
59
138
15,563
Excellent deep dive by @DrKarineTawagi on the modern systemic landscape for MIBC. A comprehensive look at current standards and the future considerations shaping the field. 🧬 #UroOnc #BladderCancer @ChiUroSociety
2
12
871
Sean Sachdev, MD retweeted
PRO bladder preservation @SeanSachdevMD vs PRO cystectomy debate @ChiUroSociety urothelial meeting #GU015 trial ongoing looking at SBRT vs hypofractionated RT in TMT Framework for pt selection for TMT by @shilpaonc et al @EuropeanUrology 💡proposed framework for the future
2
10
45
2,170
Sean Sachdev, MD retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

11
52
140
14,170
Sean Sachdev, MD retweeted
Great to reconnect with so many motivated clinical trialists, colleagues, and the #GU family at the @NRGOnc Winter Meeting #NRG2026! 2025 was a big year for NRG GU with landmark trials presented at ASTRO in plenary and clinical trials sessions (GU005, RTOG 0924, GU006) and two major bladder trials that were launched: 🔹 NRG GU014 PARRC 💉 — RT IO vs chemoRT in NMIBC 🔹 NRG GU015 ARCHER 🏹 — 20 vs 5 (adaptive) fractions chemoRT in MIBC Lots more to come in 2026! Grateful to the PIs and study teams—and especially to the patients and families who make NRG trials possible. @snseyedinMD @jmmrad @DrHowardSandler @NehaVapiwala @DrPaulNguyen @RonaldChenMD @MaryFengMD @ChadTangMD @KHoffmanMD @BrianBaumannMD @CaPsurvivorship @EdwinPosadasMD @MiyamotoDavid @abhiAsolanki @bridget_koontz @MoningiShalini @HimanshuNagarMD @UroCancer @DrSpratticus @Katie_Spina @TylerSbrt @sophia_kamran @tranpt21 @aleberlin2 @a_dalpra @ndesai2005 @SeanSachdevMD @MassGenBrigham @NRGonc #NRGOncology #RadiationOncology #GUCancer #CancerResearch #OncologyCommunity #BladderCancer #ClinicalTrials #TeamScience
6
26
2,921
Sean Sachdev, MD retweeted
🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER) Congratulations to the NRG GU015 ARCHER study team led by @UroCancer and @HimanshuNagarMD for the recent activation and launch of this cutting-edge and patient-centric bladder-sparing phase III trial that investigates many novel interventions including ultrahypofractionation/SBRT, adaptive radiation, ctDNA as a biomarker, and allows for any neoadjuvant systemic therapy. Please support this important study! #CancerResearch #RadiationOncology #Urology #MedicalOncology #MIBC #ClinicalTrial #ClinicalResearch @DrPaulNguyen @Shilpaonc @danielxingao @SeanSachdevMD @KellyStratton @AdityaBagrodia @ndesai2005 @Jonathan_Leeman @KashaniRojano @KateMRGuidance @DrMBWesterman @abhiAsolanki @MiyamotoDavid @Katie_Spina @jamesmgtsui @NRGOnc @MGHCancerCenter @urotoday @BladderCancerUS @MassGenBrigham
14 Aug 2025
PRESS RELEASE: NRG Oncology Opens New “ARCHER” Clinical Trial (NRG-GU015) Testing a Shorter Treatment Duration of Radiation Therapy for Muscle Invasive Bladder Cancer - Read more: ow.ly/6lyF50WG0GN @UroCancer @HimanshuNagarMD @MSKCancerCenter
7
12
56
8,171
Sean Sachdev, MD retweeted
On Monday, I will present the key PARTIQoL trial results at the 2024 @ASTRO_org Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!
1
11
36
4,247
Honored to host Dr. Albert Koong @ACKoongMDPhD, Chair of RadOnc at MD Andreson, as the distinguished speaker for our annual resident retreat. He started us off with a wonderful talk this morning.
2
23
1,830
Really honored and humbled to receive the 2024 Christopher Getch Clinical Excellence Award from @NeurosurgeryNM Proud to participate in the care of brain tumor patients and contribute to the education of neurosurgery residents #btsm
6
5
61
4,205
Happy to see Melanie of @LurieCancer represent at #ASCO24 in full #purpleglory
2
11
1,112
Sean Sachdev, MD retweeted
2 Oct 2023
ASTRO PLENARY Session LBA 04 Randomized trial PCI vs HA-PCI: HA-PCI is a standard of care for Small cell lung cancer
1
37
86
10,468
ASTRO Plenary: 5-fraction SBRT/SABR non-inferior at 5y compared to more protracted treatment (PACE-B). Detailed toxicity reporting, great work by @nickva1 @alison_tree @ICR_CTSU #ASTRO23
2
5
1,145
Sean Sachdev, MD retweeted
👩‍🏫📚🎉 Congratulations to our Dr. Luther Brady Educational Grant winners! 🎉📚👩‍🏫 Amulaya Yalamanchili, Northwestern University, @amulyayala Michelle Tibbs @UCSDRadMed @shelley_tibbs Ramez Kouzy @MDAndersonNews @RKouzyMD Michael Rooney @MDAndersonNews @MichaelRooney67
1
3
18
7,267
Sean Sachdev, MD retweeted
Had a blast giving a talk and hanging out with @NorthwesternMed #radonc residents and students as visiting professor! The future is bright for our field! 🌟☢️ @SeanSachdevMD @JamesRandallMD1 @SalahDajaniMD @AmulyaYala @George_E_Naoum @Zheng_Shuhua @WashURadOnc
4
7
59
5,539
Sean Sachdev, MD retweeted
TRIP did not demonstrate the superiority of 30 months vs. 6 months of ADT when combined with brachytherapy and EBRT.! Atsunori Yorozu, MD, PhD #GU23 @ASCO @OncoAlert @urotoday @PCFnews @OncBrothers @APCCC_Lugano @HemOncFellows #prostatecancer @Uromigos #MedTwitter
3
17
38
19,991
Sean Sachdev, MD retweeted
Mature outcome data from the landmark, practice changing CHHIP trial presented by @ProfJOSullivan @QubPGJCCR. 60Gy very close to being superior to 74Gy. Superb data. @EmmaHall71 @ICR_CTSU #GU23
18
48
4,572
Sean Sachdev, MD retweeted
🔥🔥 primary endpoint analysis from @nickva1 of PACE-A; SBRT versus robotic prostatectomy for #prostatecancer RCT. Co-primary toxicity endpoints (continence/bowel) #GU23 @ASCO @OncoAlert @NHSuk. N=123, SBRT had ⬇️ pad use ⬇️ sexual dysfunction but ⬆️ bowel bother. All low grade.
2
50
124
17,030
Long term results of RTOG 9802 (median FU 16.1y) showing it may be reasonable to observe some pts with low risk (GTR, Age <40) LGG. Small tumor and minimal residual (per MRI) important variables in predicting better outcomes. Molecular analyses awaited. #SNO2022 #btsm
2
10
The @atiqueahmedphd lab showing that ARF4 upregulation may serve to increase treatment resistance; a potential target for improved outcomes in GBM. #SNO2022 #btsm
4
12
From lab of @CraigHorbinski, resident Mark Youngblood showing how docetaxel may serve as a potent radiosensitizer in molecularly selected high risk meningiomas. @NeurosurgeryNM @BrainTumorInst #SNO2022
2
11